SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Ragnarsson Oskar 1971) srt2:(2013)"

Sökning: WFRF:(Ragnarsson Oskar 1971) > (2013)

  • Resultat 1-4 av 4
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Ragnarsson, Oskar, 1971, et al. (författare)
  • Cushing's syndrome: a structured short- and long-term management plan for patients in remission.
  • 2013
  • Ingår i: European journal of endocrinology / European Federation of Endocrine Societies. - 1479-683X. ; 169:5
  • Tidskriftsartikel (refereegranskat)abstract
    • One hundred years have passed since Harvey Williams Cushing presented the first patient with the syndrome that bears his name. In patients with Cushing's syndrome (CS), body composition and lipid, carbohydrate and protein metabolism are dramatically affected and psychopathology and cognitive dysfunction are frequently observed. Untreated patients with CS have a grave prognosis with an estimated 5-year survival of only 50%. Remission can be achieved by surgery, radiotherapy and sometimes with medical therapy. Recent data indicate that the adverse metabolic consequences of CS are present for years after successful treatment.In addition, recent studies have demonstrated that health-related quality of life and cognitive function are impaired in patients with CS in long-term remission. The focus of specialised care should therefore be not only on the diagnostic work-up and the early postoperative management but also on the long-term follow-up. In this paper, we review the long-term consequences in patients with CS in remission with focus on the neuropsychological effects and discuss the importance of these findings for long-term management. We also discuss three different phases in the postoperative management of surgically-treated patients with CS, each phase distinguished by specific challenges: the immediate postoperative phase, the glucocorticoid dose tapering phase and the long-term management. The focus of the long-term specialised care should be to identify cognitive impairments and psychiatric disorders, evaluate cardiovascular risk, follow pituitary function and detect possible recurrence of CS.
  •  
2.
  •  
3.
  • Ragnarsson, Oskar, 1971, et al. (författare)
  • Effect of short-term growth hormone and testosterone administration on body composition and glucose homeostasis in men receiving chronic glucocorticoid therapy.
  • 2013
  • Ingår i: European journal of endocrinology / European Federation of Endocrine Societies. - 1479-683X. ; 168:2, s. 243-51
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: Long-term pharmacological glucocorticoid (GC) therapy leads to skeletal muscle atrophy and weakness. The objective of this study was to investigate whether short-term treatment with growth hormone (GH) and testosterone (T) can increase lean mass without major impairment of glucose homeostasis in patients on GC therapy. DESIGN, MATERIALS AND METHODS: This was a prospective, open-label, randomized, crossover study. Twelve men (age 74±6 years) on chronic GC treatment participated. The effects of two weeks treatment with GH, testosterone and the combination of both, on lean body mass (LBM), appendicular skeletal muscle mass (ASMM), extracellular water (ECW), body cell mass (BCM) and plasma glucose concentrations were investigated. RESULTS: LBM increased significantly after GH (Δ1.7±1.4 kg; P=0.007) and GH+T (Δ2.4±1.1 kg; P=0.003), but not T alone. ASMM increased after all three treatment periods; by 1.0±0.8 kg after GH (P=0.005), 1.7±0.4 kg after GH+T (P=0.002) and 0.8±1.0 kg after T (P=0.018). The increase in ASMM was larger with combined treatment than either GH or T alone (P<0.05). ECW increased significantly after GH+T by 1.5±2.6 L (P=0.038) but not after GH or T alone. BCM increased slightly after single and combined treatments but the changes were not significant. Fasting glucose increased significantly after GH (Δ0.4±0.4 mmol/L, P=0.006) while both fasting (Δ0.2±0.3 mmol/L, P=0.045) and post glucose-load (Δ1.8±2.3 mmol/L, P=0.023) plasma glucose concentrations increased after GH+T. CONCLUSIONS: GH and T induce favourable and additive body compositional changes in men on chronic, low-dose GC treatment. In the doses used, combination therapy increases fasting and postprandial glucose concentration.
  •  
4.
  • Ragnarsson, Oskar, 1971, et al. (författare)
  • Neurodegenerative and inflammatory biomarkers in cerebrospinal fluid in patients with Cushing's syndrome in remission.
  • 2013
  • Ingår i: European journal of endocrinology / European Federation of Endocrine Societies. - 1479-683X. ; 169:2, s. 211-5
  • Tidskriftsartikel (refereegranskat)abstract
    • Patients with Cushing's syndrome (CS) in long-term remission have impaired cognitive function. Cerebrospinal fluid (CSF) biomarkers are important diagnostic tools in the work-up of patients with cognitive impairment. The aim of this study was to analyze neurodegenerative and inflammatory biomarkers in the CSF of patients with CS in remission.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-4 av 4

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy